These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia. Chantorn R; Shwayder T Pediatr Dermatol; 2012; 29(5):605-9. PubMed ID: 22329485 [TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374 [TBL] [Abstract][Full Text] [Related]
27. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Sperr WR; Escribano L; Jordan JH; Schernthaner GH; Kundi M; Horny HP; Valent P Leuk Res; 2001 Jul; 25(7):529-36. PubMed ID: 11377677 [TBL] [Abstract][Full Text] [Related]
28. Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria. Kaddu S; Zenahlik P; Beham-Schmid C; Kerl H; Cerroni L J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):966-78. PubMed ID: 10365929 [TBL] [Abstract][Full Text] [Related]
29. Development of a lethal mast cell disease in mice reconstituted with bone marrow cells expressing the v-erbB oncogene. von Rüden T; Kandels S; Radaszkiewicz T; Ullrich A; Wagner EF Blood; 1992 Jun; 79(12):3145-58. PubMed ID: 1350740 [TBL] [Abstract][Full Text] [Related]
30. Update on Mastocytosis (Part 2): Categories, Prognosis, and Treatment. Azaña JM; Torrelo A; Matito A Actas Dermosifiliogr; 2016; 107(1):15-22. PubMed ID: 26525106 [TBL] [Abstract][Full Text] [Related]
37. [Systemic mastocytosis. A review of current diagnostic and therapeutic approaches]. Pari F; Zamagni MD; Carnevali C; Pagani M; Rabbi C; Cantore M; Cavazzini G; Aitini E; Smerieri F Recenti Prog Med; 1999 Mar; 90(3):169-72. PubMed ID: 10228358 [TBL] [Abstract][Full Text] [Related]
38. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. Schmidt M; Hochhaus A; König-Merediz SA; Brendel C; Proba J; Hoppe GJ; Wittig B; Ehninger G; Hehlmann R; Neubauer A J Clin Oncol; 2000 Oct; 18(19):3331-8. PubMed ID: 11013272 [TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. Li WV; Kapadia SB; Sonmez-Alpan E; Swerdlow SH Mod Pathol; 1996 Oct; 9(10):982-8. PubMed ID: 8902835 [TBL] [Abstract][Full Text] [Related]
40. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]